Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided Ipilimumab Addition to Nivolumab/Relatlimab in Advanced Melanoma
NCT07504796Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Apr 2026
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by NYU Langone Health. Started Apr 2026; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07504796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07504796.